Exploring AI's Role in the Future of Drug Discovery at the Virtual Summit

Panelists at the Forefront of AI Innovation in Drug Discovery

This section shines a light on a group of panelists who are pivotal to understanding the future of artificial intelligence in pharmaceuticals. Their backgrounds not only underscore their individual expertise but also highlight how diverse backgrounds contribute to advancements in drug discovery. If you're involved in biotech or pharmaceuticals, you can't afford to overlook the insights these leaders bring to the table. In this upcoming virtual summit, titled **The State of AI in Drug Discovery**, scheduled for November 4, 2025, the panel will include experts who have a tangible impact on the evolving landscape of AI-powered drug development. Each speaker has carved out a significant niche in their respective domains, and their collective knowledge will be key in shaping the conversation around AI's integration into research and development.

Expert Lineup

**Aliza Apple, PhD** currently serves as Vice President of Catalyze360 AI/ML at Eli Lilly, leading initiatives that blend external-facing AI efforts with drug discovery. Previously, she held the COO position at Lilly Gateway Labs on the West Coast, where her focus was on cultivating the local biotech scene. Aliza has an impressive track record that includes founding Santa Ana Bio, a company dedicated to precision biologics, and working as a consultant at McKinsey, where she shaped strategies for over 20 biopharma enterprises. **Sam Rodriques, PhD**, co-founder and CEO of Edison Scientific and FutureHouse, is making waves with innovations in gene therapy and brain mapping. Prior to founding FutureHouse, which aims to create AI-driven research tools, Sam worked at the prestigious Francis Crick Institute in London. His experience blends cutting-edge research with practical applications, emphasizing the need for faster scientific progress. **Peyton Greenside, PhD**, leads BigHat Biosciences, which is leveraging machine learning to expedite the design of next-generation therapeutics. He has an educational background that includes a BA from Harvard and a PhD from Stanford, positioning him at the intersection of math and biology, where innovative solutions are born. **Marc Tessier-Lavigne, PhD**, a seasoned executive and co-founder of Xaira Therapeutics, has held numerous prestigious roles in both academia and the industry. His extensive background includes significant contributions to our understanding of brain wiring and neurodegeneration. With prestigious awards and accolades to his name, including being an officer of the Order of Canada, Marc exemplifies leadership in neuroscience and drug development. This panel isn't just a showcase of individual accomplishments; it represents a confluence of ideas and innovations that could redefine how drugs are discovered and developed. The insights shared during this virtual summit will certainly illuminate the pathways AI is carving in drug discovery. You won’t want to miss the chance to hear directly from these experts as they discuss the urgent need for infrastructure that connects AI with viable therapeutic applications. For those interested in registering, you can find more information [here](https://events.zoom.us/ev/AhU-gkQDgAxdLnotC4XH9bsSU27D7B6VJ9r7cboVW7D-XBlhuQdY~ApctLSdDOQGhoFB6oDQ77y_R7tlH2uiWKtuSw3NzxTFvnxPWyLBVS6lxOudLAszRSm_7K8poqEpmZQQtSUa7tIp3_w). In summary, the convergence of expertise among these panelists indicates a pivotal moment for AI integration in drug discovery, and their discussions promise to shed light on both opportunities and challenges ahead. Whether you're a practitioner, investor, or just fascinated by the intersection of technology and life sciences, this event is set to be both informative and possibly transformative.

Real Insights from Thought Leaders

As we wrap up this discussion on AI in drug discovery, it's clear that events like the upcoming virtual summit are indispensable for understanding where the industry is heading. Featuring luminaries like Sam Rodriques and Marc Tessier-Lavigne, this summit promises to be a treasure trove of insights into the transformative role of AI in healthcare. These are the voices that can shape future innovations and set the tone for what’s to come. The lineup is filled with experts who are pushing the boundaries of what technology can achieve in biotech. Aliza Apple and Elliot Hershberg, for instance, will tackle how strategic partnerships can enhance AI adoption within enterprises. In an industry that often moves at a glacial pace, these discussions about collaboration are crucial. They could signal a shift toward more integrated approaches to problem-solving. Don’t overlook the significance of the discussions around programmable therapeutics with Josh Meier and Peyton Greenside. This new era may redefine how we approach treatment methodologies. Their insights could be game-changing for those working in personalized medicine, illustrating the seamless intersection between AI and drug development.

Why You Should Engage

What does this all mean for you? If you're in the biotech space, this virtual summit could provide the knowledge to navigate the ever-complex interactions between technology and healthcare. With free registration, it’s an accessible way to hear directly from leaders about the practical applications of AI. Don’t miss out. This summit isn't just another conference; it's a window into the future of drug discovery, an opportunity to glean strategies and frameworks championed by the best in the field. Whether you’re a researcher or a decision-maker, the implications of these discussions will resonate far beyond the event itself. Ultimately, the role of AI in drug discovery is set to expand as we move forward. Keeping abreast of developments and expert opinions is more crucial than ever. This summit won't just highlight trends; it could very well influence the trajectory of the field for years to come.